Compare AQMS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | CLRB |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.0M |
| IPO Year | 2015 | 2008 |
| Metric | AQMS | CLRB |
|---|---|---|
| Price | $4.00 | $3.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | 54.5K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.24 |
| 52 Week High | $39.37 | $10.19 |
| Indicator | AQMS | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 59.48 |
| Support Level | $3.49 | $3.19 |
| Resistance Level | $4.40 | $3.46 |
| Average True Range (ATR) | 0.35 | 0.39 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 10.33 | 25.52 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.